These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

794 related items for PubMed ID: 19962288

  • 41. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder.
    Mezhebovsky I, Mägi K, She F, Datto C, Eriksson H.
    Int J Geriatr Psychiatry; 2013 Jun; 28(6):615-25. PubMed ID: 23070803
    [Abstract] [Full Text] [Related]

  • 42. Characterization of anxiolytic and neuropharmacological activities of Silexan.
    Kumar V.
    Wien Med Wochenschr; 2013 Feb; 163(3-4):89-94. PubMed ID: 23361848
    [Abstract] [Full Text] [Related]

  • 43. Topical lavender oil for the treatment of recurrent aphthous ulceration.
    Altaei DT.
    Am J Dent; 2012 Feb; 25(1):39-43. PubMed ID: 22558691
    [Abstract] [Full Text] [Related]

  • 44. Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited.
    Bartova L, Dold M, Volz HP, Seifritz E, Möller HJ, Kasper S.
    Eur Arch Psychiatry Clin Neurosci; 2023 Feb; 273(1):51-63. PubMed ID: 35262795
    [Abstract] [Full Text] [Related]

  • 45. [Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders].
    Lemoine P, Rouillon F, Pouget D.
    Encephale; 1996 Feb; 22(6):461-7. PubMed ID: 10901839
    [Abstract] [Full Text] [Related]

  • 46. Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder.
    Montgomery SA, Locklear JC, Svedsäter H, Eriksson H.
    Int Clin Psychopharmacol; 2014 Sep; 29(5):252-62. PubMed ID: 24394383
    [Abstract] [Full Text] [Related]

  • 47. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].
    Lemoine P, Touchon J, Billardon M.
    Encephale; 1997 Sep; 23(4):290-9. PubMed ID: 9417395
    [Abstract] [Full Text] [Related]

  • 48. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.
    Bidzan L, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV.
    Eur Neuropsychopharmacol; 2012 Dec; 22(12):847-57. PubMed ID: 22898365
    [Abstract] [Full Text] [Related]

  • 49. An evaluation of the anxiolytic SC 48,274 in generalized anxiety disorder (GAD).
    Cutler NR, Sramek JJ, Macpherson AE, Doss MG, Benes CO, Howard SF.
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):685-94. PubMed ID: 7938559
    [Abstract] [Full Text] [Related]

  • 50. Clinical assessment of the safety and efficacy of lorazepam, a new benzodiazepine derivative, in the treatment of anxiety.
    Pinosky DG.
    J Clin Psychiatry; 1978 Oct; 39(10 Pt 2):24-9. PubMed ID: 30763
    [Abstract] [Full Text] [Related]

  • 51. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study.
    Cohn JB, Wilcox CS.
    J Clin Psychiatry; 1986 Aug; 47(8):409-12. PubMed ID: 2874128
    [Abstract] [Full Text] [Related]

  • 52. A comparative study of alpidem, a nonbenzodiazepine, and lorazepam in patients with nonpsychotic anxiety.
    Diamond BI, Nguyen H, O'Neal E, Ochs R, Kaffeman M, Borison RL.
    Psychopharmacol Bull; 1991 Aug; 27(1):67-71. PubMed ID: 1677774
    [Abstract] [Full Text] [Related]

  • 53. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder.
    Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y.
    Hum Psychopharmacol; 2014 Jan; 29(1):64-72. PubMed ID: 24424707
    [Abstract] [Full Text] [Related]

  • 54. Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials.
    Kasper S.
    Wien Med Wochenschr; 2015 Jun; 165(11-12):217-28. PubMed ID: 26092515
    [Abstract] [Full Text] [Related]

  • 55. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study.
    Llorca PM, Spadone C, Sol O, Danniau A, Bougerol T, Corruble E, Faruch M, Macher JP, Sermet E, Servant D.
    J Clin Psychiatry; 2002 Nov; 63(11):1020-7. PubMed ID: 12444816
    [Abstract] [Full Text] [Related]

  • 56. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial.
    Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, Galarraga W, Struzik L, Gendron A.
    J Anxiety Disord; 2008 Dec; 22(8):1480-6. PubMed ID: 18455360
    [Abstract] [Full Text] [Related]

  • 57. The best route of administration of lavender for anxiety: a systematic review and network meta-analysis.
    Sayed AM, Morsy S, Tawfik GM, Naveed S, Minh-Duc NT, Hieu TH, Ali ZA, Shinkar A, Doheim MF, Hashan MR, Huy NT.
    Gen Hosp Psychiatry; 2020 Dec; 64():33-40. PubMed ID: 32088511
    [Abstract] [Full Text] [Related]

  • 58. Effectiveness of Silexan oral lavender essential oil compared to inhaled lavender essential oil aromatherapy on sleep in adults: a systematic review protocol.
    Greenberg MJ, Slyer JT.
    JBI Database System Rev Implement Rep; 2017 Apr; 15(4):961-970. PubMed ID: 28398982
    [Abstract] [Full Text] [Related]

  • 59. How Strong is the Evidence for the Anxiolytic Efficacy of Lavender?: Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Kang HJ, Nam ES, Lee Y, Kim M.
    Asian Nurs Res (Korean Soc Nurs Sci); 2019 Dec; 13(5):295-305. PubMed ID: 31743795
    [Abstract] [Full Text] [Related]

  • 60. Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder.
    Feltner DE, Harness J, Brock J, Sambunaris A, Cappelleri JC, Morlock R.
    CNS Neurosci Ther; 2009 Dec; 15(1):12-8. PubMed ID: 19228175
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.